NCT06864793View on ClinicalTrials.gov

Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions

Infertility, Female

Interventions

DRUG

QL1012D

A single Subcutaneous injection, 225IU

DRUG

Gonal-F®

A single Subcutaneous injection, 225IU

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY